THE SERIES A CRUNCH I recently published a whitepaper on the challenges that early stage therapeutic device companies are having raising money, along with what I hope is some meaningful advice on alternative funding options. The gist of the article is that friends and family money is still fairly easy to come by. Initial seed round funding […]
Overall, Cooley’s data pointed to a year marked by slow but steady improvement in the financing environment. In 2010, deal volumes reached a level not seen in the last five years. Median pre-money valuations increased across all deal stages and saw a significant increase in “up rounds” versus flat/down rounds. Up rounds represented 60% of all financings in 2010, a level not seen since 2008. Additionally, the percentage of recapitalization transactions fell in 2010, though the number of tranched deals remained flat from prior years.
There were 90 venture capital fundings in New England in Q1 2010, according to the PwC/NVCA MoneyTree™ Report based on data from Thomson Reuters. That represents a 23% increase over the same quarter in 2009. The recently published report details venture capital activity nationally for Q1 2010, as well as 2009 and prior years.
In their most recent survey of venture capital financing transactions, the law firm of Cooley LLP notes that pre-money valuations were up in Q1, and there was a material increase in the number of financings with pre-money valuations north of $100 million.
A complete list of the licensed SBICs in New England, updated in April 2010, including contact information, web address and a description of the types of investments made by the firm.